United States Biotechnology & Medical Research

Aduro Biotech Inc (ADRO)

Track

Track

Aduro Biotech Inc. experienced multiple divestments by key personnel throughout early 2023. The most recent transactions d'initiés occurred on August 1, 2023, involving the Chief Scientific Officer. These activities consisted entirely of sales, including planned and proposed disposals by executives, with no recorded acquisitions during this period.
Ticker: ADRO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Aduro Biotech Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
King Andrew James Chief Scientific Officer Officer
Transaction date
Sale
Price
55.25
Quantity 78,722 +1.4%
Value US$4,344,381
2.8
Greenman William Mariner Non-Executive Director
Transaction date
Planned sale
Price
366.75
Quantity 9,497 -42.7%
Value US$2,599,084
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Planned sale
Price
174.40
Quantity 11,581 +27.3%
Value US$3,272,134
3.6
ERIC DOBMEIER Officer; Director Executive Director
Transaction date
Proposed sale
Price
21.61
Quantity 25,000
Value US$540,238
2.2
Jerel Davis Non-Executive Director
Transaction date
Sale
Price
20.75
Quantity 295,808 -40.0%
Value US$6,138,223
Krishnan Mahesh Non-Executive Director
Transaction date
Planned sale
Price
23.01
Quantity 924 -42.0%
Value US$21,261
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
23.34
Quantity 5,000 -22.7%
Value US$116,718
2.2
Jerel Davis Non-Executive Director
Transaction date
Sale
Price
22.75
Quantity 36,751 -14.8%
Value US$836,085
2.2
Jerel Davis Non-Executive Director
Transaction date
Sale
Price
22.75
Quantity 123,249 -14.6%
Value US$2,803,915
2.2
Jerel Davis Non-Executive Director
Transaction date
Sale
Price
22.75
Quantity 240,000 -10.2%
Value US$5,460,000
King Andrew James Chief Scientific Officer Officer
Transaction date
Sale
Price
23.75
Quantity 2,392 -10.9%
Value US$56,806
3.2
BJERKHOLT ERIC Chief Financial Officer Officer
Transaction date
Sale
Price
23.75
Quantity 857 -2.2%
Value US$20,352
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Sale
Price
23.75
Quantity 3,700 -2.4%
Value US$87,869
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Sale
Price
23.75
Quantity 8,097 -2.6%
Value US$192,292
King Andrew James Chief Scientific Officer Officer
Transaction date
Sale
Price
24.68
Quantity 3,244 -17.7%
Value US$80,069
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Sale
Price
24.68
Quantity 4,566 -3.0%
Value US$112,700
3.2
BJERKHOLT ERIC Chief Financial Officer Officer
Transaction date
Sale
Price
24.68
Quantity 2,891 -7.2%
Value US$71,357
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Sale
Price
24.68
Quantity 7,688 -2.6%
Value US$189,757
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Planned sale
Price
24.54
Quantity 25,000 -8.4%
Value US$613,612
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.82
Quantity 10,000 -50.0%
Value US$258,183
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Planned sale
Price
25.00
Quantity 10,000 -6.5%
Value US$250,005
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Planned sale
Price
22.31
Quantity 30,000 -11.0%
Value US$669,351
3.2
BJERKHOLT ERIC Chief Financial Officer Officer
Transaction date
Sale
Price
22.29
Quantity 5,770 -14.9%
Value US$128,602
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Planned sale
Price
22.16
Quantity 10,000 -6.5%
Value US$221,642
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Sale
Price
19.69
Quantity 7,360 -4.9%
Value US$144,933
King Andrew James Chief Scientific Officer Officer
Transaction date
Sale
Price
19.69
Quantity 3,557 -22.2%
Value US$70,044
Thomas Dolca Non-Executive Director
Transaction date
Purchase
Price
21.20
Quantity 300 +3.1%
Value US$6,360
Thomas Dolca Non-Executive Director
Transaction date
Purchase
Price
21.22
Quantity 9,700 +inf%
Value US$205,834
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 5,000 -45.9%
Value US$100,000
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
18.09
Quantity 5,000 -45.9%
Value US$90,468
3.6
AKKARAJU SRINIVAS Non-Executive Director
Transaction date
Purchase
Price
14.00
Quantity 570,000 +12.4%
Value US$7,980,000
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.03
Quantity 5,000 +2.5%
Value US$65,148
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.36
Quantity 5,000 -45.9%
Value US$76,812
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.00
Quantity 2,500 -29.8%
Value US$32,500
3.2
BJERKHOLT ERIC Chief Financial Officer Officer
Transaction date
Sale
Price
12.74
Quantity 895 -3.9%
Value US$11,403
Glicklich Alan Chief Medical Officer Officer
Transaction date
Sale
Price
12.74
Quantity 2,391 -23.3%
Value US$30,464
King Andrew James Chief Scientific Officer Officer
Transaction date
Sale
Price
12.74
Quantity 2,498 -22.9%
Value US$31,827
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Sale
Price
12.74
Quantity 3,735 -2.6%
Value US$47,587
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.31
Quantity 2,500 -37.9%
Value US$33,275
2.2
Jerel Davis Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
16.00
Quantity 92,000 -14.3%
Value US$1,472,018
2.2
Jerel Davis Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
16.00
Quantity 308,000 -14.2%
Value US$4,928,062
2.2
Jerel Davis Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
16.00
Quantity 600,000 -14.2%
Value US$9,600,120
3.6
AKKARAJU SRINIVAS Non-Executive Director
Transaction date
Purchase
Price
14.00
Quantity 1,215,000 +36.0%
Value US$17,010,000
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Planned sale
Price
15.48
Quantity 6,230 -4.4%
Value US$96,440
King Andrew James Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.53
Quantity 5,000 -55.0%
Value US$67,660
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Planned sale
Price
15.17
Quantity 13,770 -8.9%
Value US$208,938
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Planned sale
Price
14.00
Quantity 5,000 -3.1%
Value US$70,000
0.9
Frohlich Tom Chief Operating Officer Officer
Transaction date
Planned sale
Price
14.00
Quantity 15,000 -8.6%
Value US$210,000
Glicklich Alan Chief Medical Officer Officer
Transaction date
Planned sale
Price
16.35
Quantity 20,000 -100.0%
Value US$326,968
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
14.44
Quantity 1,000 +1.3%
Value US$14,440
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.08
Quantity 2,000 +3.6%
Value US$26,150
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.24
Quantity 2,000 +3.8%
Value US$26,483
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.67
Quantity 929 +1.8%
Value US$12,699
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.69
Quantity 571 +1.1%
Value US$7,817
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.50
Quantity 500 +1.0%
Value US$6,750
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.75
Quantity 2,500 +5.2%
Value US$34,375
3.6
DOBMEIER ERIC President, CEO Executive Director
Transaction date
Purchase
Price
13.86
Quantity 2,000 +4.3%
Value US$27,720
Ferber Celeste SVP, GC and Secretary Officer
Transaction date
Sale
Price
2.39
Quantity 2,396 -5.8%
Value US$5,731
Templeman Blaine Chief Legal Officer Officer
Transaction date
Sale
Price
2.39
Quantity 12,369 -9.2%
Value US$29,585
ISAACS STEPHEN T President and CEO Executive Director
Transaction date
Sale
Price
2.39
Quantity 32,481 -10.4%
Value US$77,691
Nuyten Dimitry SA Chief Medical Officer Officer
Transaction date
Sale
Price
2.55
Quantity 3,538 -29.5%
Value US$9,036
Ferber Celeste SVP, GC and Secretary Officer
Transaction date
Sale
Price
2.55
Quantity 7,951 -16.2%
Value US$20,308
Templeman Blaine Chief Legal Officer Officer
Transaction date
Sale
Price
2.55
Quantity 7,951 -5.6%
Value US$20,308
van Elsas Andrea Chief Scientific Officer Officer
Transaction date
Sale
Price
3.51
Quantity 6,823 -1.5%
Value US$23,954
van Elsas Andrea Chief Scientific Officer
Transaction date
Sale
Price
1.19
Quantity 73,311 -14.1%
Value US$87,108
Ferber Celeste SVP, GC and Secretary Officer
Transaction date
Sale
Price
1.16
Quantity 408 -1.5%
Value US$475
van Elsas Andrea Chief Scientific Officer Officer
Transaction date
Sale
Price
1.16
Quantity 2,192 -0.4%
Value US$2,550
ISAACS STEPHEN T President and CEO Executive Director
Transaction date
Sale
Price
1.16
Quantity 5,897 -2.0%
Value US$6,860
Templeman Blaine Chief Legal Officer Officer
Transaction date
Planned sale
Price
1.16
Quantity 1,264 -1.1%
Value US$1,470
van Elsas Andrea Chief Scientific Officer
Transaction date
Sale
Price
1.31
Quantity 634 -0.1%
Value US$828
van Elsas Andrea Chief Scientific Officer
Transaction date
Sale
Price
1.31
Quantity 17,959 -3.3%
Value US$23,451
Ferber Celeste SVP, GC and Secretary
Transaction date
Sale
Price
1.31
Quantity 1,102 -3.9%
Value US$1,439
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-08-01 2023-08-01 S Sale
King Andrew James

Chief Scientific Officer

Officer
78,722 +1.4%
55.25
US$4,344,381 		78,722 +1.4% 55.25 US$4,344,381
2023-05-31 2023-05-30 PlS Planned sale
2.8
Greenman William Mariner
Non-Executive Director
9,497 -42.7%
366.75
US$2,599,084 		9,497 -42.7% 366.75 US$2,599,084
2023-04-26 2023-04-24 PlS Planned sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
11,581 +27.3%
174.40
US$3,272,134 		11,581 +27.3% 174.40 US$3,272,134
2023-04-24 2023-04-24 PrS Proposed sale
3.6
ERIC DOBMEIER

Officer; Director

Executive Director
25,000
21.61
US$540,238 		25,000 21.61 US$540,238
2023-04-19 2023-04-17 S Sale
2.2
Jerel Davis
Non-Executive Director
295,808 -40.0%
20.75
US$6,138,223 		295,808 -40.0% 20.75 US$6,138,223
2023-04-04 2023-04-04 PlS Planned sale
Krishnan Mahesh
Non-Executive Director
924 -42.0%
23.01
US$21,261 		924 -42.0% 23.01 US$21,261
2023-04-05 2023-04-03 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -22.7%
23.34
US$116,718 		5,000 -22.7% 23.34 US$116,718
2023-03-03 2023-03-01 S Sale
2.2
Jerel Davis
Non-Executive Director
36,751 -14.8%
22.75
US$836,085 		36,751 -14.8% 22.75 US$836,085
2023-03-03 2023-03-01 S Sale
2.2
Jerel Davis
Non-Executive Director
123,249 -14.6%
22.75
US$2,803,915 		123,249 -14.6% 22.75 US$2,803,915
2023-03-03 2023-03-01 S Sale
2.2
Jerel Davis
Non-Executive Director
240,000 -10.2%
22.75
US$5,460,000 		240,000 -10.2% 22.75 US$5,460,000
2023-02-15 2023-02-10 S Sale
King Andrew James

Chief Scientific Officer

Officer
2,392 -10.9%
23.75
US$56,806 		2,392 -10.9% 23.75 US$56,806
2023-02-15 2023-02-10 S Sale
3.2
BJERKHOLT ERIC

Chief Financial Officer

Officer
857 -2.2%
23.75
US$20,352 		857 -2.2% 23.75 US$20,352
2023-02-15 2023-02-10 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
3,700 -2.4%
23.75
US$87,869 		3,700 -2.4% 23.75 US$87,869
2023-02-15 2023-02-10 S Sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
8,097 -2.6%
23.75
US$192,292 		8,097 -2.6% 23.75 US$192,292
2023-02-02 2023-01-31 S Sale
King Andrew James

Chief Scientific Officer

Officer
3,244 -17.7%
24.68
US$80,069 		3,244 -17.7% 24.68 US$80,069
2023-02-02 2023-01-31 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
4,566 -3.0%
24.68
US$112,700 		4,566 -3.0% 24.68 US$112,700
2023-02-02 2023-01-31 S Sale
3.2
BJERKHOLT ERIC

Chief Financial Officer

Officer
2,891 -7.2%
24.68
US$71,357 		2,891 -7.2% 24.68 US$71,357
2023-02-01 2023-01-31 S Sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
7,688 -2.6%
24.68
US$189,757 		7,688 -2.6% 24.68 US$189,757
2023-02-01 2023-01-30 PlS Planned sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
25,000 -8.4%
24.54
US$613,612 		25,000 -8.4% 24.54 US$613,612
2023-01-04 2023-01-03 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
10,000 -50.0%
25.82
US$258,183 		10,000 -50.0% 25.82 US$258,183
2022-12-15 2022-12-13 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
10,000 -6.5%
25.00
US$250,005 		10,000 -6.5% 25.00 US$250,005
2022-12-02 2022-12-01 PlS Planned sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
30,000 -11.0%
22.31
US$669,351 		30,000 -11.0% 22.31 US$669,351
2022-12-02 2022-12-01 S Sale
3.2
BJERKHOLT ERIC

Chief Financial Officer

Officer
5,770 -14.9%
22.29
US$128,602 		5,770 -14.9% 22.29 US$128,602
2022-11-09 2022-11-07 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
10,000 -6.5%
22.16
US$221,642 		10,000 -6.5% 22.16 US$221,642
2022-10-11 2022-10-06 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
7,360 -4.9%
19.69
US$144,933 		7,360 -4.9% 19.69 US$144,933
2022-10-11 2022-10-06 S Sale
King Andrew James

Chief Scientific Officer

Officer
3,557 -22.2%
19.69
US$70,044 		3,557 -22.2% 19.69 US$70,044
2022-09-06 2022-09-02 B Purchase
Thomas Dolca
Non-Executive Director
300 +3.1%
21.20
US$6,360 		300 +3.1% 21.20 US$6,360
2022-09-06 2022-09-02 B Purchase
Thomas Dolca
Non-Executive Director
9,700 +inf%
21.22
US$205,834 		9,700 +inf% 21.22 US$205,834
2022-08-05 2022-08-04 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -45.9%
20.00
US$100,000 		5,000 -45.9% 20.00 US$100,000
2022-07-13 2022-07-11 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -45.9%
18.09
US$90,468 		5,000 -45.9% 18.09 US$90,468
2022-06-01 2022-05-27 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
570,000 +12.4%
14.00
US$7,980,000 		570,000 +12.4% 14.00 US$7,980,000
2022-05-27 2022-05-25 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
5,000 +2.5%
13.03
US$65,148 		5,000 +2.5% 13.03 US$65,148
2022-04-13 2022-04-11 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -45.9%
15.36
US$76,812 		5,000 -45.9% 15.36 US$76,812
2022-02-23 2022-02-18 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
2,500 -29.8%
13.00
US$32,500 		2,500 -29.8% 13.00 US$32,500
2022-02-14 2022-02-11 S Sale
3.2
BJERKHOLT ERIC

Chief Financial Officer

Officer
895 -3.9%
12.74
US$11,403 		895 -3.9% 12.74 US$11,403
2022-02-14 2022-02-11 S Sale
Glicklich Alan

Chief Medical Officer

Officer
2,391 -23.3%
12.74
US$30,464 		2,391 -23.3% 12.74 US$30,464
2022-02-14 2022-02-11 S Sale
King Andrew James

Chief Scientific Officer

Officer
2,498 -22.9%
12.74
US$31,827 		2,498 -22.9% 12.74 US$31,827
2022-02-14 2022-02-11 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
3,735 -2.6%
12.74
US$47,587 		3,735 -2.6% 12.74 US$47,587
2022-02-11 2022-02-10 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
2,500 -37.9%
13.31
US$33,275 		2,500 -37.9% 13.31 US$33,275
2022-01-05 2022-01-03 PlS Planned sale
Versant Venture Capital VII, L.P.
Large shareholder
92,000 -14.3%
16.00
US$1,472,018 		92,000 -14.3% 16.00 US$1,472,018
2022-01-05 2022-01-03 PlS Planned sale
Versant Venture Capital VII, L.P.
Large shareholder
308,000 -14.2%
16.00
US$4,928,062 		308,000 -14.2% 16.00 US$4,928,062
2022-01-05 2022-01-03 PlS Planned sale
Versant Venture Capital VII, L.P.
Large shareholder
600,000 -14.2%
16.00
US$9,600,120 		600,000 -14.2% 16.00 US$9,600,120
2022-01-05 2022-01-03 PlS Planned sale
2.2
Jerel Davis
Non-Executive Director Large shareholder
92,000 -14.3%
16.00
US$1,472,018 		92,000 -14.3% 16.00 US$1,472,018
2022-01-05 2022-01-03 PlS Planned sale
2.2
Jerel Davis
Non-Executive Director Large shareholder
308,000 -14.2%
16.00
US$4,928,062 		308,000 -14.2% 16.00 US$4,928,062
2022-01-05 2022-01-03 PlS Planned sale
2.2
Jerel Davis
Non-Executive Director Large shareholder
600,000 -14.2%
16.00
US$9,600,120 		600,000 -14.2% 16.00 US$9,600,120
2021-11-17 2021-11-15 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
1,215,000 +36.0%
14.00
US$17,010,000 		1,215,000 +36.0% 14.00 US$17,010,000
2021-11-12 2021-11-10 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
6,230 -4.4%
15.48
US$96,440 		6,230 -4.4% 15.48 US$96,440
2021-11-12 2021-11-09 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -55.0%
13.53
US$67,660 		5,000 -55.0% 13.53 US$67,660
2021-11-09 2021-11-08 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
13,770 -8.9%
15.17
US$208,938 		13,770 -8.9% 15.17 US$208,938
2021-11-09 2021-11-05 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
5,000 -3.1%
14.00
US$70,000 		5,000 -3.1% 14.00 US$70,000
2021-11-09 2021-11-05 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
15,000 -8.6%
14.00
US$210,000 		15,000 -8.6% 14.00 US$210,000
2021-06-17 2021-06-16 PlS Planned sale
Glicklich Alan

Chief Medical Officer

Officer
20,000 -100.0%
16.35
US$326,968 		20,000 -100.0% 16.35 US$326,968
2021-05-18 2021-05-14 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
1,000 +1.3%
14.44
US$14,440 		1,000 +1.3% 14.44 US$14,440
2020-12-10 2020-12-09 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,000 +3.6%
13.08
US$26,150 		2,000 +3.6% 13.08 US$26,150
2020-12-10 2020-12-08 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,000 +3.8%
13.24
US$26,483 		2,000 +3.8% 13.24 US$26,483
2020-11-23 2020-11-23 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
929 +1.8%
13.67
US$12,699 		929 +1.8% 13.67 US$12,699
2020-11-23 2020-11-20 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
571 +1.1%
13.69
US$7,817 		571 +1.1% 13.69 US$7,817
2020-11-23 2020-11-19 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
500 +1.0%
13.50
US$6,750 		500 +1.0% 13.50 US$6,750
2020-11-13 2020-11-11 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,500 +5.2%
13.75
US$34,375 		2,500 +5.2% 13.75 US$34,375
2020-11-13 2020-11-10 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,000 +4.3%
13.86
US$27,720 		2,000 +4.3% 13.86 US$27,720
2020-09-17 2020-09-15 S Sale
Ferber Celeste

SVP, GC and Secretary

Officer
2,396 -5.8%
2.39
US$5,731 		2,396 -5.8% 2.39 US$5,731
2020-09-17 2020-09-15 S Sale
Templeman Blaine

Chief Legal Officer

Officer
12,369 -9.2%
2.39
US$29,585 		12,369 -9.2% 2.39 US$29,585
2020-09-17 2020-09-15 S Sale
ISAACS STEPHEN T

President and CEO

Executive Director
32,481 -10.4%
2.39
US$77,691 		32,481 -10.4% 2.39 US$77,691
2020-08-11 2020-08-07 S Sale
Nuyten Dimitry SA

Chief Medical Officer

Officer
3,538 -29.5%
2.55
US$9,036 		3,538 -29.5% 2.55 US$9,036
2020-08-11 2020-08-07 S Sale
Ferber Celeste

SVP, GC and Secretary

Officer
7,951 -16.2%
2.55
US$20,308 		7,951 -16.2% 2.55 US$20,308
2020-08-11 2020-08-07 S Sale
Templeman Blaine

Chief Legal Officer

Officer
7,951 -5.6%
2.55
US$20,308 		7,951 -5.6% 2.55 US$20,308
2020-02-26 2020-02-25 S Sale
van Elsas Andrea

Chief Scientific Officer

Officer
6,823 -1.5%
3.51
US$23,954 		6,823 -1.5% 3.51 US$23,954
2020-01-06 2020-01-03 S Sale
van Elsas Andrea

Chief Scientific Officer
73,311 -14.1%
1.19
US$87,108 		73,311 -14.1% 1.19 US$87,108
2019-12-16 2019-12-12 S Sale Ferber Celeste

SVP, GC and Secretary

Officer
408 -1.5%
1.16
US$475 		408 -1.5% 1.16 US$475
2019-12-16 2019-12-12 S Sale van Elsas Andrea

Chief Scientific Officer

Officer
2,192 -0.4%
1.16
US$2,550 		2,192 -0.4% 1.16 US$2,550
2019-12-16 2019-12-12 S Sale ISAACS STEPHEN T

President and CEO

Executive Director
5,897 -2.0%
1.16
US$6,860 		5,897 -2.0% 1.16 US$6,860
2019-12-16 2019-12-12 PlS Planned sale Templeman Blaine

Chief Legal Officer

Officer
1,264 -1.1%
1.16
US$1,470 		1,264 -1.1% 1.16 US$1,470
2019-09-17 2019-09-13 S Sale
van Elsas Andrea

Chief Scientific Officer
634 -0.1%
1.31
US$828 		634 -0.1% 1.31 US$828
2019-09-17 2019-09-13 S Sale
van Elsas Andrea

Chief Scientific Officer
17,959 -3.3%
1.31
US$23,451 		17,959 -3.3% 1.31 US$23,451
2019-09-17 2019-09-13 S Sale
Ferber Celeste

SVP, GC and Secretary
1,102 -3.9%
1.31
US$1,439 		1,102 -3.9% 1.31 US$1,439
Explore more

More insider trading research around Aduro Biotech Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America